Go offline with the Player FM app!
Immunotherapy for Cervical Cancer
Manage episode 329548872 series 2812899
In this episode, we discuss immunotherapy treatment and biomarker testing for metastatic cervical cancer.
Our Guest:
Dr. James Bentley is a Professor and Head of the Department of Obstetrics and Gynecology at Dalhousie University, Halifax, Canada. Dr. Bentley is Past President of the International Federation of Cervical Pathology and Colposcopy (IFCPC) and the Society of Canadian Colposcopists (SCC). He is also Past-President of the Society of Gynecologic Oncology of Canada (GOC). He serves on numerous national and provincial committees involved with cervical cancer screening and gynecological cancer.
This podcast episode was sponsored by Merck Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
66 episodes
Manage episode 329548872 series 2812899
In this episode, we discuss immunotherapy treatment and biomarker testing for metastatic cervical cancer.
Our Guest:
Dr. James Bentley is a Professor and Head of the Department of Obstetrics and Gynecology at Dalhousie University, Halifax, Canada. Dr. Bentley is Past President of the International Federation of Cervical Pathology and Colposcopy (IFCPC) and the Society of Canadian Colposcopists (SCC). He is also Past-President of the Society of Gynecologic Oncology of Canada (GOC). He serves on numerous national and provincial committees involved with cervical cancer screening and gynecological cancer.
This podcast episode was sponsored by Merck Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
66 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.